Epigenetics of hematopoiesis and hematological malignancies

Deqing Hu, Ali Shilatifard*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

111 Scopus citations


Hematological malignancies comprise a diverse set of lymphoid and myeloid neoplasms in which normal hematopoiesis has gone awry and together account for ~10% of all new cancer cases diagnosed in the United States in 2016. Recent intensive genomic sequencing of hematopoietic malignancies has identified recurrent mutations in genes that encode regulators of chromatin structure and function, highlighting the central role that aberrant epigenetic regulation plays in the pathogenesis of these neoplasms. Deciphering the molecular mechanisms for how alterations in epigenetic modifiers, specifically histone and DNA methylases and demethylases, drive hematopoietic cancer could provide new avenues for developing novel targeted epigenetic therapies for treating hematological malignancies. Just as past studies of blood cancers led to pioneering discoveries relevant to other cancers, determining the contribution of epigenetic modifiers in hematologic cancers could also have a broader impact on our understanding of the pathogenesis of solid tumors in which these factors are mutated.

Original languageEnglish (US)
Pages (from-to)2021-2041
Number of pages21
JournalGenes and Development
Issue number18
StatePublished - Sep 15 2016


  • Chromatin
  • Epigenetics
  • Hematopoiesis
  • Histone

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology


Dive into the research topics of 'Epigenetics of hematopoiesis and hematological malignancies'. Together they form a unique fingerprint.

Cite this